De Novo Biotherapeutics
PrivateLast Round
Series A
Nov 25, 2022
Total Funding Raised
$9.99M
Company Overview
De Novo Biotherapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series A round in November 2022.
De Novo Biotherapeutics is a biotechnology company that develops mRNA-encoded, NK cell-engaging bi- or multi-specific antibodies for the treatment of relapsed or refractory cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
De Novo Biotherapeutics Comparables
Compare De Novo Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CREATE Medicines | 81% | |
| Therorna Inc. | 81% | |
| Eli Lilly and Company | 78% |
For institutional investors. Book with your work email.
De Novo Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 25, 2022 | ||||
| Seed | Oct 21, 2021 |
For institutional investors. Book with your work email.
De Novo Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Stonebridge Ventures | Series A |
| Heungkuk Securities | Series A |
| Atinum Investment | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 25, 2022
Raised $6M from Heungkuk Securities, Atinum Investment, and Stonebridge Ventures.
- Oct 21, 2021
$4.24M round completed.
For institutional investors. Book with your work email.
De Novo Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about De Novo Biotherapeutics's valuation, stock price, and market status.
Is De Novo Biotherapeutics a public or private company?
De Novo Biotherapeutics is a private company.
What is the current stock price of De Novo Biotherapeutics?
De Novo Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks De Novo Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is De Novo Biotherapeutics worth (valuation)?
Valuation information for De Novo Biotherapeutics is not publicly available.
Can I buy De Novo Biotherapeutics stock?
De Novo Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was De Novo Biotherapeutics's last funding round?
De Novo Biotherapeutics's most recent funding round was Series A on November 25, 2022.
Who are the main investors in De Novo Biotherapeutics?
Key investors in De Novo Biotherapeutics include Stonebridge Ventures, Heungkuk Securities, Atinum Investment.
Will De Novo Biotherapeutics IPO soon?
No public IPO plans have been announced for De Novo Biotherapeutics.
How can I track De Novo Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in De Novo Biotherapeutics's shares on secondary markets.